Close Menu

NEW YORK (360Dx) – Opko Health announced today that it has received US Food and Drug Administration approval for its point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the company's Claros 1 Analyzer.

The test quantitatively measures total PSA in whole blood from a fingerstick of blood collected by a healthcare professional. It is used in conjunction with a digital rectal exam as an aid in the detection of prostate cancer in men aged 50 years or older. There are 25 million PSA tests performed in the US annually, according to Opko.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.